Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020
- PMID: 37081745
- PMCID: PMC10124664
- DOI: 10.3201/eid2905.221294
Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020
Abstract
Recurrent Clostridioides difficile infection (RCDI) causes an increased burden on the healthcare system. We calculated RCDI incidence and identified factors associated with RCDI cases in New Haven County, Connecticut, USA, during 2015-2020 by using data from population-based laboratory surveillance. A subset of C. difficile cases had complete chart reviews conducted for RCDI and potentially associated variables. RCDI was defined as a positive C. difficile specimen occurring 2-8 weeks after incident C. difficile infection. We compared cases with and without RCDI by using multiple regression. RCDI occurred in 12.0% of 4,301 chart-reviewed C. difficile cases, showing a U-shaped time trend with a sharp increase in 2020, mostly because of an increase in hospital-onset cases. Malignancy (odds ratio 1.51 [95% CI 1.11-2.07]) and antecedent nitrofurantoin use (odds ratio 2.37 [95% CI 1.23-4.58]) were medical risk factors for RCDI. The 2020 increase may reflect the impact of the COVID-19 pandemic.
Keywords: CDI; Clostridioides difficile; Connecticut; United States; antimicrobial resistance; bacteria; bacterial infections; chronic disease epidemiology; malignancy; nitrofurantoin; nosocomial infections; recurrent CDI; recurrent Clostridioides difficile.
Figures


Similar articles
-
An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection.mSphere. 2018 May 23;3(3):e00033-18. doi: 10.1128/mSphere.00033-18. eCollection 2018 May-Jun. mSphere. 2018. PMID: 29794054 Free PMC article.
-
Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.BMC Infect Dis. 2021 May 19;21(1):456. doi: 10.1186/s12879-021-06147-y. BMC Infect Dis. 2021. PMID: 34016040 Free PMC article.
-
Incidence and risk factors for recurrent Clostridioides difficile infection in pediatric at-risk groups in selected Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) hospitals.Infect Control Hosp Epidemiol. 2024 Feb;45(2):182-187. doi: 10.1017/ice.2023.174. Epub 2023 Sep 13. Infect Control Hosp Epidemiol. 2024. PMID: 37700539
-
Evaluation of Connecticut medical providers' concordance with 2017 IDSA/SHEA Clostridioides difficile treatment guidelines in New Haven County, 2018-2019.Infect Control Hosp Epidemiol. 2021 May;42(5):549-556. doi: 10.1017/ice.2020.1237. Epub 2020 Nov 25. Infect Control Hosp Epidemiol. 2021. PMID: 33234174
-
Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.Adv Ther. 2023 Jul;40(7):3104-3134. doi: 10.1007/s12325-023-02498-x. Epub 2023 May 21. Adv Ther. 2023. PMID: 37210680 Free PMC article.
Cited by
-
Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review.World J Gastrointest Pharmacol Ther. 2024 Sep 5;15(5):95467. doi: 10.4292/wjgpt.v15.i5.95467. World J Gastrointest Pharmacol Ther. 2024. PMID: 39281262 Free PMC article. Review.
-
Advances in diagnostic assays for Clostridioides difficile infection in adults.Front Cell Infect Microbiol. 2024 Dec 10;14:1492511. doi: 10.3389/fcimb.2024.1492511. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39720791 Free PMC article. Review.
-
The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.Indian J Gastroenterol. 2025 Apr;44(2):129-141. doi: 10.1007/s12664-024-01717-9. Epub 2025 Jan 16. Indian J Gastroenterol. 2025. PMID: 39821715 Review.
-
Risk Factors for Recurrence and In-Hospital Mortality in Patients with Clostridioides difficile: A Nationwide Study.J Clin Med. 2025 Jul 10;14(14):4907. doi: 10.3390/jcm14144907. J Clin Med. 2025. PMID: 40725598 Free PMC article.
-
Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI.Microorganisms. 2023 Aug 26;11(9):2161. doi: 10.3390/microorganisms11092161. Microorganisms. 2023. PMID: 37764005 Free PMC article. Review.
References
-
- Centers for Disease Control and Prevention. Clostridioides difficile infection (CDI) tracking. 2022. [cited 2022 Dec 3]. https://www.cdc.gov/hai/eip/cdiff-tracking.html
-
- Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al.; Emerging Infections Program Clostridioides difficile Infection Working Group. Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382:1320–30. 10.1056/NEJMoa1910215 - DOI - PMC - PubMed
-
- McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:e1–48. 10.1093/cid/cix1085 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical